Introduction
Semaglutide's main weight-management trial measured outcomes across 68 weeks. In STEP 1, weekly semaglutide 2.4 mg plus lifestyle intervention produced -14.9% mean body-weight change at week 68, compared with -2.4% with placebo.
After stopping treatment in the extension study, participants regained 11.6 percentage points on average during the following year.
Week 68: the main weight-management result
STEP 1 studied adults with overweight or obesity without diabetes who received weekly semaglutide 2.4 mg or placebo with lifestyle intervention. Mean body-weight change at week 68 was -14.9% with semaglutide and -2.4% with placebo. The study did not use Ozempic, oral semaglutide, or compounded formulations as interchangeable regimens.
We may earn a commission if you start a program through links on this page. It doesn't change prices or how we sort them. Disclosure
LIVE CATALOGCurrent telehealth prices and providers
Some provider links below are affiliate links. If you start a program through one, Telehealth Ledger may earn a commission at no extra cost to you. Commissions do not change this order.
These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.
| Provider | Published price | What is included |
|---|---|---|
| #1 Sesame Care | $349, checked 20 October 2026 a month after 2 months at $199/month; plus $99/month care Visit provider Affiliate link · we may earn a commission | Wegovy® pen · Weekly injection · medication included Medication: $199/month for the first two months for eligible new self-pay patients at 0.25 or 0.5 mg, then $349/month. Offer ends December 31, 2026. Care is $99/month separately; $59/month requires an annual care commitment. Price source · checked 20 October 2026 |
| #2 RxSpan MD | $1,349, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Wegovy® · Weekly branded injection · medication included The weight-loss category card prints $1,349 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
| #3 GobyMeds | $1,695, checked 22 October 2026 a month, continuing Visit provider | Wegovy® · Weekly injection · medication includedPrice source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- Measured: Product page $99/mo membership; homepage from $49; medication separate ($199–$349/mo cash range)Last checked 7 Oct 2026Medication or membership billed separately
- MEDGm: $99 membership + medication cost (medication total not published)Medication or membership billed separately
| Provider | Published price | What is included |
|---|---|---|
| #1 Gala Health | $1,299, checked 21 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Ozempic® · Weekly injection · medication included The Ozempic product page says From $1,299/month, cash price. It says insurance may reduce the cost. That page shows no other dollar price. Price source · checked 21 October 2026 |
| #2 RxSpan MD | $1,299, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Ozempic® · Weekly branded injection · medication included The weight-loss category card prints $1,299 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- MEDGm: $171 membership + medication cost (medication total not published)Medication or membership billed separately
- Shed Rx: Starting at $599/mo. Hero $149 is CMS template bleed.Last checked 14 Sept 2026Medication included as published
| Provider | Published price | What is included |
|---|---|---|
| #1 PlexusDx | $149compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Semaglutide Oral · Daily oral tablets, provider-titrated; one price at every dose · medication included Month-to-month is $149, billed monthly. A 3-month plan is $129/mo ($387 up front), a 6-month plan is $109/mo ($654 up front), and a 12-month plan is $99/mo ($1,188 up front). The page calls $99 the starting price. Same price at every dose. Provider visit, medication, and shipping are included. No membership fee. Price source · checked 22 October 2026 |
| #2 Strut Health | $199compounded (not FDA-approved), checked 20 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded Semaglutide Oral · 30-day sublingual lozenge supply · medication includedPrice source · checked 20 October 2026 |
| #3 MyDrHank | $249compounded (not FDA-approved), checked 21 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Oral Semaglutide · Daily oral tablet · medication includedPrice source · checked 21 October 2026 |
| #4 RxSpan MD | $249compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Semaglutide Oral Capsules · Oral capsules · medication included The weight-loss category calls $249 the Regular Monthly Price for Semaglutide Capsules. A separate 12-month line of $162/mo ($1,933 upfront) is not the regular monthly price. Price source · checked 22 October 2026 |
| #5 MangoRx | $299compounded (not FDA-approved), checked 19 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Slim · Mint-flavored oral dissolving tablet; compounded semaglutide 1–6 mg with vitamin B6 · medication included Checked 19 October 2026. The plan card says $299/month, billed monthly, cancel anytime. The hero also says Starting at $299/mo. No other dollar price is on the page. The card lists the consultation, tablets, and shipping as included. Price source · checked 19 October 2026 |
Showing the 5 lowest comparable published prices from 7 eligible providers. The complete comparison includes every current catalog row.
- Curex: $49 first month starting price; exact renewal quote after intakecompounded (not FDA-approved)Last checked 7 Oct 2026Medication included as published
- MEDGm: $319/mo effective • $957 prepaid every 3 monthscompounded (not FDA-approved)Medication included as published
- MEDGm: $289/mo effective • $1,734 prepaid every 6 monthscompounded (not FDA-approved)Medication included as published
| Provider | Published price | What is included |
|---|---|---|
| #1 CoreAge Rx | $79compounded (not FDA-approved), checked 22 October 2026 a month, paying $948 for 12 months up front Visit provider Affiliate link · we may earn a commission | Compounded semaglutide injection · Injection · medication includedPrice source · checked 22 October 2026 |
| #2 yourEra | $89compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded Semaglutide month-to-month · Weekly subcutaneous injection; month-to-month · medication included Checked 22 October 2026. Month-to-month semaglutide is $89/mo after a 20% discount the page says is auto-applied. The pre-discount figure on the page is $111.25. No checkout code is printed. Medication is included. Price source · checked 22 October 2026 |
| #3 SnagRX | $99compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded semaglutide injection · Weekly subcutaneous injection · medication includedPrice source · checked 22 October 2026 |
| #4 Oak Longevity | $119compounded (not FDA-approved), checked 21 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded GLP-1 · Weekly semaglutide injection · medication included Homepage still prints GLP-1 treatments for weight loss from $119/mo. The same homepage also says prescription weight loss from $108/mo, and the weight-loss page says programs start at $190/month. Those are not one product price. Price source · checked 21 October 2026 |
| #5 Strut Health | $129compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded Semaglutide Injectable · Once-weekly subcutaneous injection · medication includedPrice source · checked 22 October 2026 |
Showing the 5 lowest comparable published prices from 19 eligible providers. The complete comparison includes every current catalog row.
- bmiMD: $149/mo effective • $447 prepaid every 3 monthscompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
- bmiMD: $129/mo effective • $774 prepaid every 6 monthscompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
- Curex: $49 first month starting price; exact renewal quote after intakecompounded (not FDA-approved)Last checked 7 Oct 2026Medication included as published
Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.
The year after stopping
The STEP 1 extension followed a subset after semaglutide and lifestyle intervention ended. Average body weight increased by 11.6 percentage points during the following year, roughly two-thirds of prior loss according to the authors. This result is useful for a maintenance conversation because it shows what happened after the study transition.
| Decision point | What the cited evidence can answer |
|---|---|
| Exact product | Confirm the approved indication, route, and formulation |
| Outcome evidence | Keep direct trials separate from indirect study comparisons |
| Practical fit | Review safety history, other medicines, follow-up, and access |
What a useful follow-up timeline tracks
A clinical timeline includes symptoms, tolerance, weight, diabetes status when relevant, other medicines, access, and longer-term goals. Wegovy's weight-management label and Ozempic's diabetes label remain distinct, even though both products contain semaglutide.
Keep product labels separate
Wegovy is the semaglutide product with the cited weight-management label. Ozempic is labeled for type 2 diabetes and related cardiovascular and kidney-risk indications. They share an ingredient, but editorial copy should not turn that into automatic interchangeability.
Route and formulation questions belong on the oral-versus-injectable page, not in a borrowed dosing table.
A timeline should include a maintenance question
ADA guidance describes obesity pharmacotherapy as chronic treatment when clinically appropriate and supports continuing monitoring after goals are reached. The discussion includes benefit, safety, tolerance, burden, and alternatives.
That means a timeline should end with a follow-up question, not a sales claim about a finish line.
Safety comes before a scale target
Severe persistent abdominal pain, repeated vomiting, dehydration, allergic symptoms, and clinically important vision changes in a person with diabetes need prompt assessment. Those problems should not be reframed as normal milestones.
Readers should use the exact label and care team for symptom-specific decisions.
Urgent symptoms are more important than whether a weekly weight target was reached.
What the cited sources establish
STEP 1 measured weekly semaglutide 2.4 mg plus lifestyle intervention through 68 weeks in adults with overweight or obesity without diabetes. Its extension followed a subset after treatment and lifestyle intervention ended. Those results create a long-horizon evidence frame, not a validated weekly curve for Wegovy, Ozempic, oral semaglutide, or a compounded product.
STEP 1's 68-week result and its extension's one-year follow-up should be read together: one describes treatment-period weight change, and the other describes average change after study treatment ended. That context supports a maintenance conversation before access, tolerance, pregnancy plans, or preference force a decision. It also keeps Wegovy's weight-management evidence distinct from Ozempic's diabetes label and from oral-product studies.
The STEP 1 result is most useful when paired with its study frame: weekly semaglutide 2.4 mg, lifestyle intervention, adults without diabetes, and a 68-week endpoint. The extension then adds a separate maintenance signal after study treatment ended. A real follow-up timeline can track tolerance, weight, diabetes status when relevant, other medicines, and access, while keeping a different product or formulation from being folded into the same expected curve.
Questions that change the next review
A semaglutide timeline visit can connect weight change with tolerance, nutrition, activity, diabetes status, other medicines, access, and the expected label-specific follow-up. That broader review is more useful than attempting to reproduce another participant's curve or treating one quiet month as proof that treatment has failed.
A useful timeline conversation asks which outcomes matter besides weight and whether symptoms, access, diabetes care, or another medicine changed during the same period. That keeps the 68-week trial result in the right clinical frame.
Product details that still need verification
The page does not create a personal deadline, recommend dose changes, or turn STEP 1 withdrawal data into a restart plan. It also keeps Wegovy's weight-management evidence distinct from Ozempic's diabetes label and from oral-product evidence. Symptom safety takes priority over a chart milestone.
STEP 1 studied weekly semaglutide 2.4 mg plus lifestyle intervention. Withdrawal evidence matters for maintenance conversations. Wegovy and Ozempic have distinct labeled uses. A personal plateau needs a clinical review, not an unsupervised switch. Use STEP 1 to understand the evidence horizon. Do not turn a trial average into a deadline or a reason to change treatment alone.
Use the current product label and prompt clinical care for urgent symptoms or medication changes.
Common questions
- How long does semaglutide take to work?
- STEP 1 evaluated outcomes through 68 weeks. Individual timing differs and a first-month change does not predict a final result.
- Can I use Ozempic results as a Wegovy timeline?
- No. The products have distinct labels and studied indications.
- What happens after stopping?
- The STEP 1 extension found substantial average regain after withdrawal in its follow-up group. Discuss an individualized plan with a clinician.
- Should I increase the dose if progress is slow?
- Do not self-adjust. Review response and tolerability with the prescribing team.
A timeline should improve the next clinical conversation
Use STEP 1 to understand the evidence horizon. Do not turn a trial average into a deadline or a reason to change treatment alone.
Already on a wegovy plan? See which of 4 providers charge less than yours
Starting from scratch? How to get compounded oral semaglutide online
Sources
- STEP 1PubMed · Accessed 28 August 2026
Primary 68-week obesity trial.
- STEP 1 extensionPubMed · Accessed 28 August 2026
Post-withdrawal follow-up.
- Wegovy prescribing informationFDA · Accessed 28 August 2026
Weight-management product label.
- Ozempic prescribing informationFDA · Accessed 28 August 2026
Diabetes product label.
- ADA Standards of Care 2026American Diabetes Association · Accessed 28 August 2026
Chronic-care and monitoring context.
Refresh triggers
- A new FDA label or Medication Guide
- A new major clinical-trial publication
- An ADA or AGA guideline update
- A material change to the verified provider registry